Skip to main content
Psychedex

1Provenance card

the boundary, as counts

Sources

3027 with DOI

0 strong · 20 moderate · 10 weak

Compilations

12026-05-08T17:10:03.088Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

33last ruled 2026-06-04

1 awaiting a ruling

Issued documents

42026-10-19T20:31:09.172Z

notice · info card · emergency

Searches

221 with no results

queries and counts on the build

Claims checked

6244 supported

44 supported · 18 not

Correspondence

0received

consent field ships in Phase 4

Edges

221

derivations recorded for this entity

Complete over 30 sources, 1 compilation, and 33 decisions.Not here: the private journal (never); 1 proposal awaiting a ruling (listed as pending only).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/clonazolam/archive

Timeline

what happened, newest first — claims, searches and artifacts stay inside Build

  1. 2026-10-19issueIssued info_card
  2. 2026-10-02srcDetectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays
  3. 2026-10-02srcThe emergence of new psychoactive substance (NPS) benzodiazepines: A review.
  4. 2026-10-02srcThe Risk Factors and Mortality Among Patients With Different Combination Patterns of Opioids and Benzodiazepines: A Retrospective Study.
  5. 2026-10-02srcDesigner benzodiazepines: A new challenge
  6. 2026-10-02srcDesigner Benzodiazepines: Another Class of New Psychoactive Substances.
  7. 2026-10-02srcCharacterization and identification of eight designer benzodiazepine metabolites by incubation with human liver microsomes and analysis by a triple quadrupole mass spectrometer.
  8. 2026-10-02srcClonazolam a new designer benzodiazepine intoxication confirmed by blood concentration.
  9. 2026-10-02srcMetabolic profiling of clonazolam in human liver microsomes and zebrafish models using liquid chromatography quadrupole Orbitrap mass spectrometry.
  10. 2026-10-02srcA method for improved detection of 8-isoprostaglandin F2 and benzodiazepines in wastewater.
  11. 2026-10-02srcQuantification of new psychoactive substances in Australian wastewater
  12. 2026-10-02srcDesigner benzodiazepine dependence and the difficulties of outpatient management; a case report.
  13. 2026-10-02srcOccurrence and time course of NPS benzodiazepines in Sweden - results from intoxication cases in the STRIDA project.
  14. 2026-10-02srcDesigner benzodiazepines: a report of exposures recorded in the National Poison Data System, 2014-2017.
  15. 2026-10-02srcNon-fatal intoxications involving the novel benzodiazepine clonazolam: case series from the Emerging Drugs Network of Australia - Victoria project.
  16. 2026-10-02srcThe Evolution Toward Designer Benzodiazepines in Drug-Facilitated Sexual Assault Cases
  17. 2026-10-02srcA Fatal Case Report Resulting from the Abuse of the Designer Benzodiazepines Clonazolam and Flualprazolam in Conjunction with Dried Opium Poppy Pods
  18. 2026-10-02srcIncreasing prevalence of designer benzodiazepines in impaired driving: A 5-year analysis from 2017 to 2021
  19. 2026-10-02srcChallenges of Diagnosing and Managing Designer Benzodiazepine Dependence and Withdrawal: A Case Report.
  20. 2026-10-02srcClonazolam Intoxication Case Report: Danger of Designer Benzodiazepines.
  21. 2026-10-02srcChanges over time in novel benzodiazepines contributing to fatal overdoses in Victoria, Australia
  22. 2026-10-02srcDesigner benzodiazepines' pharmacological effects and potencies: How to find the information
  23. 2026-10-02srcManagement of benzodiazepine misuse and dependence.
  24. 2026-10-02src'New/Designer Benzodiazepines': An Analysis of the Literature and Psychonauts' Trip Reports
  25. 2026-10-02srcRecent findings and advancements in the detection of designer benzodiazepines: a brief review
  26. 2026-10-02srcNovel Designer Benzodiazepines: Comprehensive Review of Evolving Clinical and Adverse Effects
  27. 2026-10-02srcThe Psychonauts' Benzodiazepines; Quantitative Structure-Activity Relationship (QSAR) Analysis and Docking Prediction of Their Biological Activity.
  28. 2026-10-02srcDetoxification after use of new psychoactive substances purchased online
  29. 2026-10-02srcSchedules of Controlled Substances: Placement of Clonazolam in Schedule I (permanent proceedings).
  30. 2026-10-02srcSchedules of Controlled Substances: Temporary Placement of Etizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I.
  31. 2026-10-02srcCritical Review Report: Clonazolam. Expert Committee on Drug Dependence (43rd ECDD).
  32. 2026-09-04issueIssued emergency
  33. 2026-09-04issueIssued info_card
  34. 2026-09-04issueIssued notice
  35. 2026-07-03proposaldependence · taper
  36. 2026-06-04proposal30 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
  37. 2026-06-04publicationPublication — backfill
  38. 2026-05-08revisionRevision 1
  39. 2026-05-08absenceSearched ClinicalTrials.gov for "clonazolam" — no results
  40. 2026-05-08genGeneration — pipeline-v5 · with 3 morepipeline-v5
  41. 2026-05-08rungeneration run

The same entries, as forms: six forms.